The latest progress on novel coronavirus vaccination in kidney transplant recipients

Due to long-term use of immunosuppressant, poor immune function and a higher risk of critical diseases after novel coronavirus pneumonia in kidney transplant recipients, it is of significance to deliver prophylactic vaccination for this high-risk population. Studies have shown that the immune reaction of kidney transplant recipients to novel coronavirus vaccine is significantly lower than that of healthy counterparts. Standard vaccination program in the United States, such as 2 doses of messenger RNA (mRNA) vaccine, fails to provide sufficient protection for kidney transplant recipients. Many studies have proven that increasing the frequency of vaccination for kidney transplant recipients may enhance the vaccine efficacy. Nevertheless, the role of adjusting immunosuppressive therapy in increasing vaccine efficacy remains to be elucidated. In this article, the importance, effectiveness and particularity of novel coronavirus vaccine for kidney transplant recipients and the effect of immunosuppressive therapy on the efficacy of novel coronavirus vaccine were reviewed, aiming to provide reference on the vaccination for kidney transplant recipients. (English) [ FROM AUTHOR]

Research highlights on kidney transplantation in 2021: voices from China.

Over the past 70 years, kidney transplantation has become not only the most mature but also the highest-success-rate surgery among all organ transplantation surgeries. However, the long-term survival of kidney transplant recipients is still challenged by such key factors as ischemia-reperfusion injury related to kidney transplantation, rejection, chronic renal allograft dysfunction, renal allograft fibrosis, immunosuppressive therapy, infections and others. Relevant fundamental and clinical studies have emerged endlessly. At the same time, the research related to kidney transplantation also becomes a new hot spot accordingly in the context of the normalization of novel coronavirus pneumonia. This article reviewed the cutting-edge hot spots in relation to the fundamental and clinical aspects of kidney transplantation together with relevant new techniques and new visions. The studies included in this article focused on the reports published by Chinese teams that are more applicable to the current situation of kidney transplantation in China, for the purpose of providing new thoughts and strategies for the diagnosis and treatment of kidney transplantation related issues in China. (English) [ FROM AUTHOR] 经过近 70 年的发展，肾移植已成为所有器官移植手术里最成熟，也是成功率最高的手术，但肾移 植相关缺血 - 再灌注损伤、排斥反应、慢性移植肾失功、移植肾纤维化、免疫抑制治疗与感染等仍是影响肾移植 受者长期生存的关键因素，相关的基础与临床研究层出不穷。同时，在新型冠状病毒肺炎疫情常态化的背景下， 与肾移植相关的研究也是一个新的热点。本文就 2021 年肾移植基础与临床相关的前沿热点以及肾移植相关的新 技术、新视野做一综述，且介绍的研究以中国团队发表的报道为主，更符合中国肾移植的实际情况，以期为我国 肾移植相关问题的诊疗提供新的思路和策略. (Chinese) [ FROM AUTHOR] Copyright of Organ Transplantation / Qi Guan Yi Zhi is the property of Organ Transplantation Editorial Department and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full . (Copyright applies to all s.)